Company intelligence / Profile preview

Ingredi

Hangzhou, Zhejiang, Chinaingredipharma.com ↗

Ownership: Private
Development stage: Other

Overview

Ingredi is a clinical-stage biotechnology company based in Hangzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and immunology through the design of highly selective targeted therapies. Ingredi leverages its internal medicinal chemistry and drug discovery capabilities to advance a pipeline of proprietary candidates. Its lead programs are currently progressing through early-stage clinical trials, aiming to provide more effective treatment options for patients with cancer and inflammatory conditions.

Therapeutic areas: OncologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Ingredi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ingredi.

Explore the full profile